Belite Bio (NASDAQ:BLTE) CEO Sells 365 Shares

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CEO Yu-Hsin Lin sold 365 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total transaction of $65,827.75. Following the completion of the transaction, the chief executive officer owned 170,569 shares of the company’s stock, valued at approximately $30,762,119.15. This represents a 0.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Belite Bio Stock Performance

Shares of Belite Bio stock opened at $166.26 on Friday. The firm’s 50-day simple moving average is $152.11 and its 200-day simple moving average is $159.84. Belite Bio, Inc. Sponsored ADR has a twelve month low of $60.00 and a twelve month high of $200.00. The firm has a market cap of $6.66 billion, a P/E ratio of -65.72 and a beta of -1.22.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Friday, May 15th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. On average, equities analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Mizuho reduced their target price on Belite Bio from $223.00 to $215.00 and set an “outperform” rating on the stock in a report on Tuesday, May 26th. Zacks Research raised Belite Bio from a “hold” rating to a “strong-buy” rating in a report on Monday, July 20th. HC Wainwright lifted their price objective on Belite Bio from $200.00 to $214.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Belite Bio in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $204.40.

Institutional Trading of Belite Bio

Several hedge funds have recently modified their holdings of BLTE. EverSource Wealth Advisors LLC acquired a new stake in shares of Belite Bio in the second quarter valued at approximately $147,000. Marshall Wace LLP acquired a new position in Belite Bio during the 2nd quarter worth $547,000. BNP Paribas Financial Markets bought a new position in Belite Bio in the 2nd quarter valued at $190,000. JPMorgan Chase & Co. boosted its position in Belite Bio by 45.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,809 shares of the company’s stock valued at $726,000 after buying an additional 3,052 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Belite Bio by 380.7% in the 3rd quarter. UBS Group AG now owns 11,334 shares of the company’s stock valued at $839,000 after buying an additional 8,976 shares during the period. 0.53% of the stock is owned by institutional investors.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: The FDA granted priority review to Belite Bio’s tinlarebant New Drug Application for Stargardt disease. The accelerated review sets an expected decision date in February 2027 and follows positive Phase 3 data, potentially shortening the path to commercialization for the company’s lead program. BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
• Positive Sentiment: HC Wainwright raised its price target to $214 from $200 and maintained a Buy rating, signaling continued analyst confidence in tinlarebant’s commercial potential. Belite Bio Price Target Increase
• Positive Sentiment: Second-quarter results exceeded expectations: Belite Bio reported a loss of $0.54 per share versus the consensus estimate of a $0.73 loss. The earnings beat may support sentiment, while management’s corporate update and earnings call provided additional detail on the company’s development programs. Belite Bio Second Quarter 2026 Results
• Neutral Sentiment: Belite Bio remains a clinical-stage biotechnology company, so its valuation and stock performance remain highly dependent on regulatory decisions, clinical execution and the future launch of tinlarebant. Belite Bio Q2 2026 Earnings Call Transcript
• Negative Sentiment: The company continues to report net losses, and analysts expect a full-year loss. With shares trading near their yearly high and at a loss-based price-to-earnings valuation, investors may be taking profits despite the positive FDA and earnings developments.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.